Stocks & Investing
Thu, December 3, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, June 8, 2020
[ 12:00 AM ] - WOPRAI
Wed, April 29, 2020
[ 12:00 AM ] - WOPRAI
Tue, March 17, 2020
[ 12:00 AM ] - WOPRAI
Tue, December 10, 2019
[ 12:00 AM ] - WOPRAI
Tue, October 29, 2019
[ 12:00 AM ] - WOPRAI
Thu, September 5, 2019
[ 12:00 AM ] - WOPRAI
Thu, July 18, 2019
[ 12:00 AM ] - WOPRAI
Mon, October 22, 2018
[ 12:00 AM ] - WOPRAI
Wed, August 15, 2018
[ 12:00 AM ] - WOPRAI
Mon, June 4, 2018
[ 12:00 AM ] - WOPRAI
Wed, March 9, 2016
[ 12:00 AM ] - WOPRAI
Tue, May 26, 2015 Konstantinos Aprilakis Initiated (BPMC) at Hold and Held Target at $110 on, Dec 3rd, 2020
Konstantinos Aprilakis of Stifel, Initiated "Blueprint Medicines Corporation" (BPMC) at Hold and Held Target at $110 on, Dec 3rd, 2020.
Konstantinos has made no other calls on BPMC in the last 4 months.
There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with Konstantinos's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $96 on, Monday, November 2nd, 2020
- David Lebovitz of "Morgan Stanley" Downgraded from Buy to Hold on, Friday, October 30th, 2020
These are the ratings of the 3 analyists that currently disagree with Konstantinos
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $120 on, Thursday, October 29th, 2020
- Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $122 on, Friday, October 16th, 2020
- Andrew Berens of "Morgan Stanley" Maintained at Buy with Increased Target to $100 on, Tuesday, October 13th, 2020
